The Beauty Health Company (SKIN) Reports In-Line Q4 EPS
The Beauty Health Company (NASDAQ: SKIN) reported Q4 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $96.8 million versus the consensus estimate of $87.22 million.
GUIDANCE:
The Beauty Health Company sees Q1 2024 revenue of $77-83 million, versus the consensus of $85.5 million.
Financial Guidance as of March 2024
First Quarter 2024 |
|
Net sales | $77 – $83 million |
Adjusted EBITDA(1) | ($6) – ($9) million |
|
|
Fiscal Year 2024 |
|
Net sales | Flat to low-single digit % growth |
Adjusted EBITDA(1) | > $40 million |
__________________________
(1) See "Non-GAAP Financial Measures" below.
Financial guidance reflects the following assumptions:
For earnings history and earnings-related data on The Beauty Health Company (SKIN) click here.